Results 151 to 160 of about 722,278 (319)
, 2012 [[abstract]]In order to reduce the signature verification time quite, some investigations on DSA-type and RSA-type digital signatures have been done to achieve batch verification.
黃明祥;Hwang, Min-Shiang
core
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
A Thesis: A CRYPTOGRAPHIC STUDY OF SOME DIGITAL SIGNATURE SCHEMES.
, 2003 In this thesis, we propose some directed signature schemes. In addition, we have discussed their applications in different situations. In this thesis, we would like to discuss the security aspects during the design process of the proposed directed ...
balyan raghuvanshi, Kumar Manoj
core
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining
Molecular Oncology, EarlyView.IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis +3 more
wiley +1 more source
Molecular Oncology, EarlyView.Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens +6 more
wiley +1 more source
Generalization of Proxy Signature Based on Elliptic Curves
, 2012 [[abstract]]In the past, proxy signature schemes were usually proposed to deal with one or two separate proxy conditions each. To make a difference, in this paper, the authors shall present a generalized version of proxy signature scheme.
黃明祥;Hwang, Min-Shiang
core
Molecular Oncology, EarlyView.Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi +14 more
wiley +1 more source
PULPO: pipeline of understanding large-scale patterns of oncogenomic signatures. [PDF]
BioinformaticsPortasany-Rodríguez M +11 more
europepmc +1 more source
A Multi-policy Threshold Signature Scheme with Traceable Participant Cosigners
, 2009 [[abstract]]In a (t, n) threshold scheme, the secret can be reconstructed by the cooperation of t or more users. With this basic concept, Lee devised a threshold signature scheme with multiple signing policies in 2001.
Chu, C. H.;Lin, H. F.;Chang, C. C.;Chen, C. Y.
core